Lu Yongjie, Liu Yunqiang, Liao Shunyao, Tu Wenling, Shen Ying, Yan Yuanlong, Tao Dachang, Lu Yilu, Ma Yongxin, Yang Yuan, Zhang Sizhong
Department of Medical Genetics and Division of Human Morbid Genomics, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.
Diabetic Center and Institute of Transplantation, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
Oncotarget. 2016 Jul 12;7(28):43162-43176. doi: 10.18632/oncotarget.9012.
The ectopic activation of NR0B1 is involved in the development of some cancers. However, the regulatory mechanisms controlling NR0B1 expression are not well understood. Therefore, the epigenetic modifications promoting NR0B1 activation were examined in this study. NR0B1 protein was detected in cancerous tissues of more than 50% of human lung adenocarcinoma (ADCA) cases and tended to be expressed in low-differentiated cancerous tissues obtained from males. Nevertheless, NR0B1 activation in ADCA has not previously been correlated with DNA demethylation. NR0B1 expression was not detected in 293T cells, although it contains a hypomethylated NR0B1 promoter. Treating 293T cells with a histone deacetylase inhibitor increased acetylated histone H4 binding to the NR0B1 promoter and activated NR0B1 expression. In contrast, treatment with histone methylase inhibitors decreased the methylation of histones H3K9 and H3K27 and slightly induced NR0B1 transcription. Furthermore, the level of acetyl-histone H4 binding to the NR0B1 promoter increased, whereas the occupancy of H3K27me3 was lower in cancerous tissues than in non-cancerous tissues. Similar histone occupancies were confirmed in a comparison of cancerous tissues with strong, moderate and negative NR0B1 expression. In conclusion, this study shows that CpG methylation within the NR0B1 promoter is not involved in the in vivo regulation of NR0B1 expression, whereas the hyperacetylation of histone H4 and the unmethylation of histones H3K9 and H3K27, and their binding to the NR0B1 promoter results in decondensed euchromatin for NR0B1 activation.
NR0B1的异位激活与某些癌症的发生发展有关。然而,控制NR0B1表达的调控机制尚未完全明确。因此,本研究对促进NR0B1激活的表观遗传修饰进行了检测。在超过50%的人肺腺癌(ADCA)病例的癌组织中检测到了NR0B1蛋白,且倾向于在男性来源的低分化癌组织中表达。然而,此前ADCA中NR0B1的激活与DNA去甲基化并无关联。尽管293T细胞含有低甲基化的NR0B1启动子,但未检测到NR0B1的表达。用组蛋白去乙酰化酶抑制剂处理293T细胞可增加乙酰化组蛋白H4与NR0B1启动子的结合,并激活NR0B1的表达。相反,用组蛋白甲基化酶抑制剂处理可降低组蛋白H3K9和H3K27的甲基化水平,并轻微诱导NR0B1的转录。此外,与非癌组织相比,癌组织中与NR0B1启动子结合的乙酰化组蛋白H4水平升高,而H3K27me3的占有率降低。在NR0B1表达强、中、阴性的癌组织比较中也证实了类似的组蛋白占有率情况。总之,本研究表明NR0B1启动子内的CpG甲基化不参与NR0B1表达的体内调控,而组蛋白H4的高乙酰化以及组蛋白H3K9和H3K27的去甲基化及其与NR0B1启动子的结合会导致常染色质解聚以激活NR0B1。